Nutra Pharma Corp.
Bringing Healthcare Solutions to the World
 
NPC Blog
NPC Blog
2009 Archives
2008 Archives
2007 Archives
2006 Archives
Search Archives
Archives
  • December 2008 (1)
  • October 2008 (1)
  • September 2008 (1)
  • August 2008 (2)
  • July 2008 (2)
  • June 2008 (4)
  • May 2008 (1)
  • April 2008 (1)
  • March 2008 (4)
  • February 2008 (1)
  • April 2007 (1)
  • December 2006 (1)
  • October 2006 (1)
  • September 2006 (1)
  • July 2006 (2)
  • June 2006 (3)
  • Blog Updates
    Signup here and receive blog posts directly in your inbox.

     

    Subscribe in a reader

     
    E-Alerts
    Signup to receive news and announcements from Nutra Pharma
    Name:
    Email:

    Yes, in addition to e-alerts, please sign me up to receive Nutra Pharma Blog postings via email.

    Infinite Menus, Copyright 2006, OpenCube Inc. All Rights Reserved.
    NPC Blog

    Nutra Pharma’s 2008 Accomplishments

    Posted on Dec 23rd, 2008 by Rik J. Deitsch

    2008 turned out to be an exciting and important year for completing large drug discovery milestones at Nutra Pharma.  As the year quickly comes to a close, I wanted to take a moment to reflect back on our top accomplishments…

    Medical Devices

    • We began developing and marketing through our medical devices subsidiary, Designer Diagnostics, the first-ever environmental test kit for the rapid detection of Nontuberculous Mycobacteria

    Drug Discovery

    • We acquired the remaining interest in our drug discovery holding, ReceptoPharm, which transitioned it into a Nutra Pharma wholly-owned subsidiary
    • We received final approval from the Florida Department of Agriculture and Consumer Services to begin a trial using RPI-MN for treating Feline Leukemia Virus (FeLV). This study will not only help us develop a possible model for studying RPI-MN as a treatment for HIV in humans, but if successful, RPI-MN will be the first-ever treatment for FeLV, a virus that currently affects 2% to 3% of the cat population in the United States
    • We successfully completed a 15-month Phase IIb/IIIa trial using RPI-78M as a treatment for Adrenomyeloneuropathy (AMN). We expect the fully-audited results from this study to be available in early 2009
    • In addition to completing this Phase IIb/IIIa clinical trial, we also announced that initial reports and feedback from physicians involved with this study reported that patients had experienced no adverse side effects from RPI-78M. This led us to the decision to continue providing RPI-78M under compassionate release to patients previously enrolled in the study
    • We renewed our collaborative agreement with the Centers for Disease Control and Prevention (CDC) to study RPI-78M and RPI-MN as a possible therapy for Rabies
    • We received our first clinical drug supply contract from Celtic Biotech in Dublin, Ireland, which represented the first revenue for our drug discovery subsidiary, ReceptoPharm. As we continue into 2009, we plan to expand this outsourced drug production to additional biotechnology firms. This will allow us to fully utilize our GMP-qualified production facility and will also provide us with an additional revenue stream

    Additional Outreach

    • We re-launched our corporate blog to help build transparency between Nutra Pharma and those interested in our drug discovery research and corporate strategy
    • We were mentioned in several articles published in various pharmaceutical industry trade publications
    • We received an invitation by BlogBurst to extend the reach of our blog postings to be included in media outlets such as USA Today, Gannett, Reuters, FoxNews, Houston Chronicle and many others


    del.icio.us:Nutra Pharma’s 2008 Accomplishments digg:Nutra Pharma’s 2008 Accomplishments spurl:Nutra Pharma’s 2008 Accomplishments wists:Nutra Pharma’s 2008 Accomplishments simpy:Nutra Pharma’s 2008 Accomplishments newsvine:Nutra Pharma’s 2008 Accomplishments blinklist:Nutra Pharma’s 2008 Accomplishments furl:Nutra Pharma’s 2008 Accomplishments reddit:Nutra Pharma’s 2008 Accomplishments fark:Nutra Pharma’s 2008 Accomplishments blogmarks:Nutra Pharma’s 2008 Accomplishments Y!:Nutra Pharma’s 2008 Accomplishments smarking:Nutra Pharma’s 2008 Accomplishments magnolia:Nutra Pharma’s 2008 Accomplishments segnalo:Nutra Pharma’s 2008 Accomplishments gifttagging:Nutra Pharma’s 2008 Accomplishments

     


    Update on the Phase IIb Clinical Trial Data

    Posted on Oct 3rd, 2008 by David Isserman

    For the past week, we have fielded several phone calls and emails asking us about the status of our clinical data for our Phase IIb study in treating Adrenomyeloneuropathy (AMN). While we are working diligently to get this information compiled, analyzed, and published as quickly as possible, it has taken a little longer than expected due to a lag in data collection from the last several patients in the Trial.

    We understand how anxious and excited you are to learn more about the results of this trial. We are too! Please bear with us as we continue to process the data. We expect to have it available towards the end of October.

    Update: November 17, 2008

    The last patient’s visit occurred in August 2008 and currently, the data from the trial are being prepared for analysis, with results expected during early 2009.


    del.icio.us:Update on the Phase IIb Clinical Trial Data digg:Update on the Phase IIb Clinical Trial Data spurl:Update on the Phase IIb Clinical Trial Data wists:Update on the Phase IIb Clinical Trial Data simpy:Update on the Phase IIb Clinical Trial Data newsvine:Update on the Phase IIb Clinical Trial Data blinklist:Update on the Phase IIb Clinical Trial Data furl:Update on the Phase IIb Clinical Trial Data reddit:Update on the Phase IIb Clinical Trial Data fark:Update on the Phase IIb Clinical Trial Data blogmarks:Update on the Phase IIb Clinical Trial Data Y!:Update on the Phase IIb Clinical Trial Data smarking:Update on the Phase IIb Clinical Trial Data magnolia:Update on the Phase IIb Clinical Trial Data segnalo:Update on the Phase IIb Clinical Trial Data gifttagging:Update on the Phase IIb Clinical Trial Data

     


    Older Posts »

     
    Quick Nav
     
    Recent News
     
    December 08, 2008
    Nutra Pharma Receives Clinical Drug Supply Contract


    November 17, 2008
    Nutra Pharma Announces Provision of RPI-78M under Compassionate Release to Adrenomyeloneuropathy (AMN) Patients


    August 14, 2008
    Nutra Pharma Announces Initial Positive Safety Data from Clinical Study in Adrenomyeloneuropathy (AMN)


     
     
    Announcements
    Click Here to read about Nutra Pharma's top accomplishments of 2008.
     
     
    NPC
    Privacy Policy